Clinical trials: Cancer, Advanced Solid Tumors
Cholangiocarcinoma, Urothelial Cancer
A Study of TAS-120 in Patients With Advanced Solid Tumors
This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120).
- Conditions
- Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors
- Trial name
- NCT02052778
- Testing
- Futibatinib
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 407 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumor
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
- Trial name
- BiPAVE-001 (NCT06635785)
- Testing
- AI-081
- Where
- 21 sites in United States
- Volunteers
- 387 people
- Sponsor
- OncoC4, Inc.
Malignant Melanoma, Lung Cancer, or Colorectal Cancer
A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn't express on normal tissues.
- Trial name
- NCT05190185
- Testing
- TAA06 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Solid Tumor, Non-Hodgkin Lymphoma
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.
- Trial name
- NCT05221385
- Testing
- Gentulizumab
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Solid Tumors
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients.
- Trial name
- NCT00932126
- Testing
- PF-03758309
- Where
- 3 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Pfizer
Cancer
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors
The purpose of this study is to determine whether IHL-305 (irinotecan liposome injection) is safe and effective in the treatment of advanced solid tumors.
- Trial name
- NCT00364143
- Testing
- IHL-305 (irinotecan liposome injection)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Yakult Honsha Co., LTD
Solid Cancers
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced solid tumors who are refractory to treatment…
- Trial name
- NCT01209143
- Testing
- Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumours, Breast Cancer
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03507543
- Testing
- IMP4297
- Where
- 3 sites in Australia
- Volunteers
- 39 people
- Sponsor
- Impact Therapeutics, Inc.
Advanced or Metastatic Solid Tumors
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit.
- Trial name
- TITAN (NCT03454243)
- Testing
- RXDX-106
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.
This is an open-label, single-arm, dose escalation clinical study to evaluate the safety and preliminary efficacy of OVV-01 Injection in patients with advanced solid tumors, following both intravenous (iv.) and intratumoral (it.)…
- Trial name
- NCT07648472
- Testing
- OVV-01 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Joint Biosciences Ltd.
Solid Tumors, Glioblastoma
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.
- Trial name
- NCT01905228
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incuron
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Breast Cancer, Neoplasm Metastasis
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
- Trial name
- NCT01118975
- Testing
- Vorinostat, Lapatinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Solid Tumor, Peritoneal Metastases
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
This is an open-label, non-randomized, multicenter, Phase 1/2a study to evaluate the safety and potential efficacy of Allocetra-OTS in the treatment of advanced solid tumor malignancy as monotherapy or in combination with an…
- Conditions
- Solid Tumor, Peritoneal Metastases, Peritoneal Cancer
- Trial name
- NCT05581719
- Testing
- Allocetra-OTS, Nivolumab, Tislelizumab
- Where
- 6 sites in Israel, Spain
- Volunteers
- 14 people
- Sponsor
- Enlivex Therapeutics RDO Ltd.
Advanced Solid Tumors, Multiple Myeloma
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
This study will determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of single agent ONC201 in patients with advanced solid tumors or multiple myeloma.
- Trial name
- NCT02609230
- Testing
- ONC-201
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Fox Chase Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in treating patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT00119236
- Testing
- tanespimycin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Head and Neck Cancer
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of docetaxel in treating patients with advanced solid…
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00002901
- Testing
- docetaxel
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Tumor or Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety, pharmacokinetics (study of what the body does to a drug), and pharmacodynamics (study of what a drug does to the body) of JNJ-42756493, a pan-fibroblast growth factor receptor…
- Trial name
- NCT01703481
- Testing
- JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3
- Where
- 37 sites in United States, France and 1 more
- Volunteers
- 188 people
- Sponsor
- Janssen Research & Development, LLC
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Solid Tumor, Adult, Colorectal Cancer
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b.
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06598007
- Testing
- CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Crossignal Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.